CLOs on the Move


 
ilumed is a company that helps providers, payers, and other healthcare organizations transition to value-based care models, which focus on quality of health outcomes rather than quantity of services.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ilumed.com
  • 775, W Indiantown Rd
    Jupiter, FL USA 33458
  • Phone: 800.481.8745

Executives

Name Title Contact Details

Similar Companies

Bayshore HealthCare

At Bayshore, we believe in creating special moments for our clients each and every day, whether at the bedside, on the phone or in the clinic. These moments touch the lives of our clients and our employees, and they guide the way we run our business. These moments inspire, change and encourage us. They are what we call the Bayshore difference. Bayshore HealthCare is one of the country`s leading providers of home and community health care services and is a Canadian-owned company.

Absolute Awakenings Treatment Center

Absolute Awakenings is a New Jersey-based drug and alcohol addiction treatment center that offers long-term recovery solutions for those struggling with addiction and alcoholism.

Walnut Hills Retirement Cmmty

Walnut Hills Retirement Cmmty is a Walnut Creek, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accredo Health Group, Inc.

Accredo Health Group, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.